Moderna’s US-French partner DNA Script has raised additional $35m as a second tranche of a Series C financing to advance its Enzymatic DNA Synthesis platform, Syntax.
Novo Holdings, together with Saminvest, Vækstfonden, the European Investment Fund and its three co-founders have put €110m in the first fund of Sound Bioventures AB.
The new year begins with good news.
Novo Holdings is set to invest €86m in 21st.BIO A/S – a new Danish bioindustrial scale-up company – to boost the production of proteins.
Ocular gene therapy specialist Gyroscope Therapeutics Holdings plc is to be acquired by Novartis AG for up to $1.5bn.
Dutch metabolic disease specialist NorthSea Therapeutics NV has baged US$80m in a Series C fundraising co-led by Ysios Capital and Forbion Growth.
French-British magnetic trap specialist Depixus has raised €30,6m to develop a commercial instrument based on the company’s MAGNA technology.
Ichnos Sciences Inc. has licenced the gobal rights on its IL-1RAP antagonistic antibody ISB 880 to Almirall SA for the treatment of autoimmune disorders.
Biologicals and vaccine specialist CSL Ltd is set to acquire Swiss Vifor Pharma Ltd for CHF10.9bn.
German Apogenix AG has received a €26m in funding for a pivotal Phase III study of its CD95 ligand blocker asunercept for the treatment of COVID-19 patients.